VYGR•benzinga•
Voyager Selects Tau Silencing Gene Therapy Development Candidate For Alzheimer's Disease; VY1706 Demonstrates Significant Reductions Of Tau At Low Doses In NHP Study; IND, CTA Filings Anticipated In 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 20, 2024 by benzinga